Peptide education
Chonluten
Chonluten is the tripeptide Glu-Asp-Gly, called EDG or T-34 in the Khavinson bioregulator literature, where it is filed as a lung and bronchial peptide. The filing is thinner than it sounds. The direct Chonluten evidence is one 2022 immune-cell study and older rat gastric-ulcer work; the human respiratory claims trace to a secondary review and product pages; and part of the strong lung gene-expression data people cite for it actually belongs to Bronchogen, a different peptide.
Chonluten is a real literature peptide with a respiratory label, but the human case for it is a review paragraph and marketing pages, not a trial. What sellers call Chonluten ranges from AC-7 capsules and lingual drops to 20 mg vials whose listed molecular weights do not all agree with EDG.
Overview
Quick answer
Literature Chonluten and market Chonluten are not always the same thing. The literature usually points to EDG/Glu-Asp-Gly, while branded products may describe AC-7 peptide complexes in capsules or drops, and research sellers may list lyophilized vials with conflicting molecular-weight information.
What is it?
In the literature, Chonluten is EDG: the tripeptide Glu-Asp-Gly, also called T-34, from the Khavinson short-peptide family, positioned around lung and bronchial tissue. What the market sells under the name is less consistent.
What do people use it for or talk about?
Respiratory support, bronchitis-type claims, low-oxygen adaptation, older-adult respiratory resilience, gastric and mucosal repair, anti-aging. The support is cell work, a rat model, a secondary review, and product pages. A detailed human trial is not among the sources.
What route, amount, and schedule details are documented?
Laboratory and market numbers, not human instructions: 100 ng/mL in THP-1 cells, 0.5 micrograms subcutaneously for 5 days in a rat ulcer model, 0.2 to 0.4 mg daily in AC-7 capsules, 0.105 mg per lingual-drop serving, and 20 mg research vials. Those numbers belong to different products and cannot be merged into one regimen.
Why does product form matter?
Because the evidence does not transfer across forms. EDG cell studies say nothing about an AC-7 capsule, and Bronchogen's bronchial gene-expression data, often quoted nearby, is not Chonluten data at all. Each product needs its own identity and its own evidence.
Reported practice
Commonly reported protocol
Branded capsule and lingual products. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Multiple literature sources identify Chonluten with EDG, Glu-Asp-Gly, or T-34 in the Khavinson short-peptide family.
The strongest direct Chonluten paper studied THP-1 monocytes and macrophages and reported changes in inflammatory cytokines, kinase signaling, adhesion, and STAT1-related signaling.
Respiratory human-benefit claims appear mainly in a secondary review and product pages. They refer to clinical studies but do not give a detailed primary trial report.
The market uses Chonluten for AC-7 supplements, lingual products, research-use vials, and listings that imply injectable use without documenting a finished sterile injectable product. That makes product identity and dose comparison unusually fragile.
No FDA-approved Chonluten drug or current U.S. label was found, and FDA/FTC materials caution against disease or health-product claims without adequate backing.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Chonluten is a respiratory peptide. | Human evidence is weak. A review and product pages describe respiratory and bronchial use, including chronic bronchitis with an asthmatic component and respiratory support in older adults, but no detailed primary human trial is available for Chonluten. | The 2022 THP-1 paper lists Chonluten as a respiratory-lung peptide and reports immune-cell signaling effects. That supports biological interest, not a clinical respiratory outcome. | Branded capsule and lingual pages market Chonluten around lungs, bronchi, respiratory function, and broader tissue support. Those pages show market positioning, not patient-outcome evidence. | Respiratory discussion is real in the sources. The jump from respiratory bioregulator to reliable treatment for lung disease is the part the evidence does not yet support. |
| Chonluten has anti-inflammatory effects. | Human anti-inflammatory evidence for Chonluten is still weak. | THP-1 monocyte/macrophage work reported reduced inflammatory cytokine expression in LPS-stimulated differentiated cells, changes in ERK1/2, JNK, and p70S6K signaling, reduced adhesion to activated endothelial cells, and STAT1 nuclear-translocation findings. | Marketing and bioregulator discussions often turn that biology into broad wellness language, but the direct support is still laboratory biology. | The THP-1 findings show immune-cell signaling changes in the lab. Reduced inflammation in people would need human outcome data. |
| Chonluten treats COPD, asthma, chronic bronchitis, pneumonia, or ARDS. | The support is secondary-review and product-page claim language, not a strong primary trial record. Disease-treatment wording would outrun the evidence. | Respiratory positioning and immune-cell signaling explain why the topic comes up, but plausibility is not a disease endpoint. | Product pages and gray-market pages use respiratory-disease language, including chronic bronchitis, asthma, acute respiratory disease, and rehabilitation claims. | This remains a weakly documented claim with missing primary human evidence, not a demonstrated treatment effect. |
| Chonluten supports gastric or mucosal repair. | A human gastric-ulcer regimen or patient outcome is not available to carry this claim. | Older EDG/T-34 material describes rat gastric-ulcer and HSP70-related biology, including a subcutaneous rat regimen after ulcer formation and a promoter-complementarity hypothesis. | Some market pages extend Chonluten beyond respiratory tissue into the stomach, intestines, liver, or pancreas. | This remains preclinical and product-claim context unless stronger human evidence is added. |
| Chonluten is a longevity or anti-aging peptide. | Chonluten-specific human longevity or lifespan outcome evidence was not found. | The broader Khavinson peptide literature includes geroprotection and gene-regulation language, but Chonluten improving aging outcomes in humans has not been shown. | Product and regimen-style pages may attach anti-aging, rehabilitation, or broad prevention language to Chonluten. | This is mostly marketing and family-level extrapolation, not a human longevity claim. |
| Chonluten is a mitochondrial peptide. | Human evidence for a mitochondrial outcome is not available. | Chonluten is discussed around respiratory, immune-signaling, transport-modeling, promoter, and GI hypotheses, not a direct mitochondrial target. | Taxonomy and wellness marketing can pull bioregulators into mitochondrial or longevity categories, but the cited evidence does not carry a Chonluten-specific mitochondrial claim. | The Chonluten evidence does not back a mitochondrial claim. |
| A Chonluten COA confirms product identity and injectable quality. | A COA helps with identity and quality review; it does not show human efficacy. | A purity percentage does not answer sterility, endotoxin control, concentration accuracy, counterion content, salt form, residual solvents, storage stability, or whether the product matches EDG or an AC-7 complex. | One research-vial page reports 99.845% purity, 26.86 mg measured weight, and endotoxin pass for a nominal 20 mg vial, while also listing a molecular weight that conflicts with other EDG listings. | A COA can be a clue, but it does not resolve Chonluten's identity and injectable-quality questions. |
Bottom line
Main takeaway
Chonluten is a bioregulator name with a respiratory theme, early lab work, and thin human-use claims. The case for it as a lung treatment has not been made.
Price out the forms separately: EDG research material, AC-7 capsules, AC-7 lingual drops, and research vials with conflicting molecular weights are different products wearing one name. Keep Chonluten's evidence separate from Bronchogen's while you are at it.
The load-bearing sources are the 2022 THP-1 paper, the T-34 gastric-ulcer and HSP70 literature, and the 2020 review that carries the oral respiratory claims. Note what is missing between them: a primary human trial report.
Identity
What it is
Chonluten is EDG, the tripeptide Glu-Asp-Gly, known in older Khavinson-linked material as T-34. The family tradition assigns it to the lungs and bronchi.
The direct evidence is modest and oddly shaped. The strongest Chonluten-specific experiment is a 2022 study in THP-1 monocytes and macrophages showing inflammatory-signaling changes; the older T-34 work is a rat gastric-ulcer model with an HSP70 angle. Neither is a lung outcome in a person, and the human respiratory claims come from a 2020 review that summarizes studies it does not detail.
Some of the best-looking lung data in this neighborhood is not Chonluten's. Bronchogen, a neighboring respiratory bioregulator, has the more detailed bronchial epithelial gene-expression work, and the two get blended in marketing. They are different peptides with different evidence.
Commerce makes it worse. The name covers AC-7 capsule complexes, lingual drops with sub-milligram AC-7 servings, and research vials, with at least one molecular-weight listing that conflicts with EDG. "Chonluten" on a label is a claim, not a verified identity.
How people talk about it online
Online, Chonluten is sold as respiratory support: bronchi, lung function, older-adult resilience, plus the usual anti-aging and broad tissue-support language. The sellers' certainty is not matched by the sources.
The product layer spans supplement capsules, lingual drops, research vials, and pharmacy-style pages that imply injectable use, with "clinical studies" rhetoric but no surfaced trial. One vial listing pairs a 99.845% purity claim with a molecular weight that conflicts with other EDG listings.
Watch for borrowed evidence in these discussions: detailed bronchial gene-expression findings get quoted as Chonluten support when they are Bronchogen data. The names sit next to each other in catalogs; the molecules are not the same.
Use context
Routes, doses, and cycle patterns
Chonluten has no FDA label or well-documented human dosing standard in the reviewed evidence. The concrete patterns come from cell work, a rat model, secondary review claims, and marketed products. Route and amount depend on the setting: in vitro concentrations, animal exposure, capsule AC-7 amounts, lingual AC-7 amounts, research-vial listings, and injection-adjacent market pages are separate contexts, not one protocol.
Human studies and product labels
THP-1 monocyte exposure
- Purpose
- Immune-cell signaling and proliferative readouts
- Context
- In vitro human monocyte cell-line study
- Route
- Cell-culture exposure
- Amount
- 100 ng/mL Chonluten, alone or with 100 ng/mL LPS
- Frequency
- Overnight exposure in monocytes
- Duration
- Overnight
The THP-1 study is the strongest direct Chonluten experiment here. It helps explain anti-inflammatory and signaling interest, but it is not a human dose, route, or outcome.
THP-1-derived macrophage exposure
- Purpose
- Cytokine, kinase, adhesion, and STAT1 signaling readouts
- Context
- In vitro differentiated THP-1 macrophage study
- Route
- Cell-culture exposure
- Amount
- 100 ng/mL Chonluten, alone or with 100 ng/mL LPS
- Frequency
- Repeated time-point sampling
- Duration
- 2, 4, 8, and 12 hours
The study reported reduced inflammatory signaling readouts and changes in adhesion and signaling pathways. Those findings are helpful for mechanism, but they do not provide a human route or schedule.
Rat gastric-ulcer T-34 regimen
- Purpose
- HSP70 expression and mucosal repair after induced gastric ulcer
- Context
- Animal and review-level EDG/T-34 material
- Route
- Subcutaneous in the rat model
- Amount
- 0.5 micrograms in 0.5 mL saline
- Frequency
- Daily after ulcer formation
- Duration
- 5 days, with tissue sampled on day 7
This is an animal regimen, not a human gastric-ulcer protocol. It is useful because it shows where the GI and HSP70 rationale comes from.
Review-level oral EDG respiratory claims
- Purpose
- COPD, chronic bronchitis with asthmatic component, hypoxia adaptation, and standard-therapy support
- Context
- Secondary review passage, not a primary trial report
- Route
- Oral in the review-level claim
- Amount
- Not reported in the review passage
- Frequency
- Not reported in the review passage
- Duration
- Not reported in the review passage
This is the main human-claim source, but it lacks the trial details needed for a reliable clinical claim.
Real-world discussion
Branded capsule and lingual products
- Purpose
- Lung and respiratory discussion
- Context
- Russian product materials and bioregulator vendors
- Route
- Oral capsules and lingual drops in product materials
- Amount
- 0.2 to 0.4 mg daily in AC-7 capsules; 0.105 mg per lingual-drop serving
- Frequency
- Daily in product materials
- Duration
- Not consistently documented across products
These numbers belong to different products and cannot be merged into one regimen, and no consistent community course pattern is documented in the cited material. Reported as context, not a recommendation.
What varies
- Identity: EDG/Glu-Asp-Gly, AC-7 complex, and seller-listed Chonluten vials may not be interchangeable.
- Route: cell-culture exposure, rat subcutaneous exposure, oral capsules, lingual drops, research vials, and listings that imply injectable use create different risk questions.
- Amount: 100 ng/mL in vitro, 0.5 micrograms in a rat model, 0.105 mg lingual AC-7, 0.2 to 0.4 mg capsule AC-7, and 20 mg vial formats are not interchangeable dosing contexts.
- Human evidence: respiratory claims are still missing the primary trial details that would make them strong clinical claims.
- Product quality: molecular-weight conflicts, route drift, COA limits, sterility, endotoxin, salt form, residual solvents, and storage conditions matter more than a headline purity percentage.
Human data
Human evidence
Thin to the point of absence. The only human-use material is a 2020 review repeating oral EDG claims for COPD, chronic bronchitis with an asthmatic component, and low-oxygen performance, plus product pages that invoke clinical studies without producing one. No detailed, peer-reviewed primary trial of Chonluten for any respiratory outcome is in the cited record. The human case is a citation chain that ends at a summary.
Evidence maturity
Chonluten's direct evidence is cell and animal work; the human respiratory claims rest on secondary review and product pages.
Rat gastric-ulcer and HSP70 gene-expression studies established EDG in the Khavinson literature.
A 2022 THP-1 monocyte and macrophage study reported inflammatory-signaling and adhesion changes.
A 2020 review and product pages claim oral respiratory benefit for COPD and chronic bronchitis, but no detailed primary trial is public.
AC-7 capsules, lingual drops, and research vials share the Chonluten name with conflicting molecular-weight and identity details.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Review-level oral EDG respiratory claims | People described in secondary review material, including COPD and chronic bronchitis with asthmatic component | Secondary review passage | EDG / Chonluten review literature | The review reports respiratory and hypoxia-related benefit language, but it lacks enough primary-trial detail to verify methods, dose, endpoints, comparator, or adverse events. | This is a secondary summary. It is too limited for a strong treatment claim without the original human studies. | Weak |
| THP-1 monocyte/macrophage Chonluten study | Human cell-line model, not patients | In vitro mechanistic study | Laboratory Chonluten / EDG research context | Reported changes in inflammatory cytokines, kinase signaling, adhesion, STAT1 nuclear translocation, and related immune-cell readouts. | Cell-line findings are early biology, not human efficacy, dosing, route, durability, or safety. | Preclinical |
| Rat gastric-ulcer and HSP70 material | Rats with induced gastric ulcer | Animal and review-level preclinical evidence | EDG/T-34 preclinical context | Reported a subcutaneous T-34 regimen after ulcer formation with HSP70 and mucosal-repair discussion in older Khavinson-linked literature. | Animal GI findings cannot be translated into a human respiratory, gastric-ulcer, or longevity claim without human confirmation. | Preclinical |
Cautions
Safety and unknowns
- Chonluten does not have a strong human safety package. Missing items include pharmacokinetics, immunogenicity, interaction data, reproductive toxicology, carcinogenicity, route-specific tolerability, and long-term adverse-event characterization.
- Route drift is a major safety problem. Oral capsules, lingual drops, research-use vials, listings that imply injectable use, cell-culture exposure, and animal subcutaneous exposure each create different absorption, sterility, and dose-translation questions.
- The 2022 THP-1 study found enough biological activity to affect inflammatory and signaling readouts. Chonluten is not biologically inert just because human risks are poorly characterized.
- Respiratory disease, asthma, COPD, pneumonia, ARDS, gastric-ulcer, anti-aging, cancer-prevention, and chemotherapy-support claims are medical-condition claims. Without primary human trials, they remain marketing language rather than demonstrated benefit.
- Product identity varies across sellers and formulations. A consumer may see EDG, AC-7 peptide complex, capsules, drops, or vials under the same Chonluten name.
- COAs and purity percentages leave open sterility, endotoxin, residual solvents, salt form, counterion content, stability, shipping, reconstitution, representative sampling, and whether the listed molecular weight matches the intended peptide.
Product quality
A vial label is only a starting point
Chonluten's core quality issue is identity. Literature EDG, branded AC-7 products, and research-vial listings point to different products unless lot-specific testing ties them together.
One research-vial listing reports 99.845% purity, measured vial weight, and endotoxin pass, but the same source family contains a molecular-weight conflict against other EDG listings.
Branded capsule and lingual products list very small AC-7 amounts, while research or injectable-implying listings may show milligram vial formats. Those are different exposure and quality situations.
Identity
EDG/Glu-Asp-Gly, T-34, AC-7 complex, and seller-listed Chonluten may not refer to the same analytically confirmed material.
Molecular weight and formula
The available listings include values that converge on 319.27 g/mol for EDG and another Chonluten page listing 418.407 g/mol, which is a real identity warning.
Route and form factor
Capsules, lingual drops, lyophilized vials, and injection-adjacent products require different quality evidence.
Sterility and endotoxin
Purity and identity testing can still leave sterile manufacturing, endotoxin control, container integrity, and handling open.
Concentration and dose math
Microgram animal exposures, sub-milligram AC-7 servings, and milligram vial formats are easy to confuse if the product form is ignored.
Marketing context
Product pages can borrow respiratory or bioregulator language while selling a product that lacks drug-level safety and efficacy review.
Mechanism
How it is proposed to work
Chonluten is proposed to act like other ultrashort Khavinson peptides: small enough to interact with cellular transport and signaling systems, and possibly able to influence gene-expression programs. The strongest direct Chonluten paper shows immune-cell signaling changes in a lab model, while older EDG/T-34 material points to gastric-ulcer, HSP70, antioxidant, and promoter-interaction hypotheses.
In THP-1 monocytes and macrophages, Chonluten was associated with changes in ERK1/2, JNK, p70S6K, inflammatory cytokine expression, adhesion to activated endothelial cells, and STAT1 nuclear-translocation findings.
The broader Khavinson framework proposes that ultrashort peptides may affect gene expression through interactions with DNA, histones, promoter regions, and cellular transporters. For EDG/T-34, the cited literature discusses an HSP70 promoter-complementarity hypothesis.
Transport modeling literature discusses PEPT1, PEPT2, LAT transporters, and EDG docking, but that does not confirm human pharmacokinetics or target engagement.
Bronchogen has more detailed bronchial epithelial gene-expression work than Chonluten in the cited English-language sources, so Bronchogen data cannot serve as direct Chonluten evidence.
Chonluten (Glu-Asp-Gly) is a Khavinson-lineage tripeptide positioned for lung tissue claims, with proposed gene-expression modulation from the lineage's bioregulator framework.
FAQ
Common questions
What is chonluten?
Chonluten is a Khavinson-lineage bioregulator peptide positioned for lung and respiratory claims. Its evidence is the Russian bioregulator literature plus animal and cell work.
What do bioregulator courses look like?
The documented numbers belong to different products: 0.2 to 0.4 mg daily AC-7 capsules, 0.105 mg lingual-drop servings, and 20 mg research vials. They cannot be merged into one regimen.
Is there human evidence?
Nothing meeting controlled-trial standards. The claims rest on the lineage's own publications.
Details
Technical details
Sources
References
- 1.
2022 THP-1 Chonluten study. Avolio et al., 2022, International Journal of Molecular Sciences. Direct Chonluten evidence in THP-1 monocytes/macrophages, including sequence identity, concentrations, cytokines, kinase signaling, and STAT1 observations.
- 2.
2012 T-34 gastric-ulcer abstract. Khavinson et al., 2012, Bulletin of Experimental Biology and Medicine. Primary T-34 abstract preview on antioxidant and anti-inflammatory gene-expression regulation in gastric-ulcer context.
- 3.
2012 EDG gerontology review. Kuznik, Lin’kova, and Khavinson, 2012, Advances in Gerontology. Review-level source summarizing T-34/EDG gastric-ulcer and HSP70 findings, including a reported animal regimen and promoter-binding hypothesis.
- 4.
2016 EDG gene-regulation paper. Khavinson, Lin’kova, and Tarnovskaya, 2016, Bulletin of Experimental Biology and Medicine. Short-peptide gene-regulation framework placing EDG among peptides linked to ulcer-related gene-expression changes.
- 5.
2020 Molecules EDG review. Khavinson, Linkova, and Dyatlova, 2020, Molecules. Secondary review source for oral EDG respiratory and hypoxia claims, with limited primary-trial detail.
- 6.
FDA approval database check. FDA Orange Book and DailyMed. Best official U.S. databases for approved-drug and label status; no Chonluten approval or label was found in the source materials.
- 7.
FDA unapproved-drug explainer. FDA Unapproved Drugs. Official FDA explanation that unapproved drugs have not been reviewed for safety, effectiveness, or quality.
- 8.
FDA supplement claim framework. FDA claim-framework pages on dietary supplements and structure/function claims. Important for disease-claim boundaries.
- 9.
FTC health-product guidance. FTC Health Products Compliance Guidance. Official substantiation standard for health-product marketing claims.
- 10.
FDA peptide-development guidance. FDA peptide-development guidance. Useful for the safety-unknowns discussion, especially immunogenicity and clinical-pharmacology gaps.
- 11.
Verified Peptides Chonluten listing. Verified Peptides. Research-vial seller with lot-specific purity, weight, endotoxin data, but also a sequence-to-molecular-weight inconsistency that increases identity risk.
- 12.
Chonluten capsule product page. Chonluten capsule product page. Shows AC-7 composition, capsule form, supplement-style positioning, and broad respiratory claims.
- 13.
Chonluten lingual product page. Chonluten lingual product page. Shows AC-7 composition, dietary-supplement positioning, broad tissue scope, and “clinical studies” language without surfacing trial details.
- 14.
iPept Chonluten claims page. iPept Chonluten lingual page. Strong example of claim overextension, including respiratory, GI, anti-aging, and cancer-adjacent language under “not a medicinal product.”
- 15.
Chonluten spec and seller pages. Third-party seller and chemical-spec pages for Chonluten. These listings converge on 319.27 g/mol for EDG and expose conflicts with other Chonluten listings.